MYL-1601D biosimilar product provides an alternative treatment option for insulin aspart. 1 Introduction Maintaining good glycemic control is critical to prevent or delay microvascular and macrovascular complications in patients with type 1 (T1D) and type 2 diabetes mellitus (T2D) [1,2,3]. The pr...